Revised Milestone 1 for Grant Reference BB/M013278/1
Lead Research Organisation:
University College London
Department Name: Oncology
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
| Bart Vanhaesebroeck (Principal Investigator) |
Publications
Bilanges B
(2017)
Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism.
in Nature communications
| Description | In our grant BB/I007806, genetic inactivation of class III PI3K was shown to result in metabolic sensitization in cells and induce a specific signal transduction pathway and metabolic alterations. Using the current award, we have shown that pharmacological intervention with this kinase shows exactly the same phenotype in cells. This now sets the scene to test whether pharmacological intervention in mice will also result in metabolic sensitization. |
| Exploitation Route | We are exploring to generate our own inactivators of this kinase, possibly in collaboration with the LMB-MRC in Cambridge. |
| Sectors | Healthcare,Pharmaceuticals and Medical Biotechnology |
| Description | Deciphering PI3K biology in health and disease |
| Amount | € 495,745 (EUR) |
| Funding ID | Phd |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 11/2015 |
| End | 10/2019 |
| Title | vps34 mutant mice |
| Description | Mice in which the vps34 PI 3-kinase is inactivated in a constitutive or conditional manner. This mouse line can be used in pre-clinical models of disease, such as cancer and diabetes. We may ultimately licence these mice to pharma, as we have done for our other PI3K mutant mice. |
| Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
| Year Produced | 2011 |
| Provided To Others? | Yes |
| Impact | - Extensive collaborations in UK, US and France. - Allowed other people to apply for grants using these materials - successful bid to BBSRC for programme grant follow-up funding |
| Description | Collaboration with Novartis Research Institution - Boston USA |
| Organisation | Novartis Institutes for BioMedical Research (NIBR) |
| Country | United States |
| Sector | Private |
| PI Contribution | We have received a small molecule inhibitor from Novartis under MTA, and tested this compound to validate our genetic data |
| Collaborator Contribution | Novartis provided a small molecule inhibitor against the vps34 Pi 3-kinase under MTA, |
| Impact | A manuscript describing the results of these studies has now been published (Bilanges et al - Nature Communications 2017) |
| Start Year | 2016 |